Examples of clinically approved nanomedicine
| Year of approval | Name | Nanotechnology platform | Therapeutic agent | Indication | Refs |
|---|---|---|---|---|---|
| 1995 (FDA)1996 (EMA) | Doxil/Caelyx | Liposome (PEGylated) | Doxorubicin | HIV-associated Kaposi sarcoma, ovarian cancer,metastatic breast cancer, multiple myeloma | [9] |
| 1996 (FDA) | DaunoXome | Liposome (non-PEGylated | Daunorubicin | HIV-associated Kaposi sarcoma | [10] |
| 2002 (FDA) | Eligard | poly(D, L-Lactide-co-glycolide) (PLGH) | Leuprorelin acetate | Prostate cancer | [11] |
| 2005 (FDA)2008 (EMA) | Abraxane | Nanoparticle albumin bound | Paclitaxel | Advanced non-small-cell lung cancer, metastatic breast cancer, metastatic pancreatic cancer | [12] |
| 2006 (FDA) | Oncaspar | polyethyleneglycol (PEG) protein conjugate | L-asparaginase | Leukemia | [13] |
| 2009 (EMA) | MEPACT | Liposome (non-PEGylated) | Mifamurtide | Osteosarcoma | [14] |
| 2015 (FDA) | MM-398/Onivyde | Liposome (PEGylated) | Irinotecan | Metastatic pancreatic cancer | [15] |
| 2017 (FDA) | VYXEOS | Liposome | Daunorubicin and cytarabine | Acute myeloid leukemia | [16] |
| 2019 (FDA) | Polivy (polatuzumab vedotin-piiq) | Antibody-drug conjugate | Monomethyl auristatin E | Relapsed diffuse large B-cell lymphoma | [17] |
FDA: Food and Drug Administration; EMA: European Medicines Agency